Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of S103 Cells in Patients With Progressive or Refractory Multiple Sclerosis：An Open-Label, Single-Arm, Exploratory Clinical Study

NCT07587125 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT07587125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07587125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of S103 Cells in Patients With Progressive or Refractory Multiple Sclerosis：An Open-Label, Single-Arm, Exploratory Clinical Study
Lead sponsor
Xijing Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
May 8, 2026
Completion date
November 30, 2029
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, multiple sclerosis (ms) primary progressive, multiple sclerosis (ms) secondary progressive, refractory multiple sclerosis